(Q34037773)

30 July 2017

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial (English)

1 reference

30 July 2017

0 references

osteogenesis imperfecta

0 references

Oliver Semler

20

0 references

Christine P Burren

Christine P Burren

6

0 references

Jordi Anton

Jordi Antón

4

0 references

Outi Mäkitie

Outi Mäkitie

12

0 references

Robert D. Steiner

Robert D Steiner

22

0 references

Silvano Adami

2

Silvano Adami

1 reference

30 July 2017

11

Roman Lorenc

1 reference

30 July 2017

13

Craig F Munns

1 reference

30 July 2017

Nick Bishop

1

1 reference

30 July 2017

S Faisal Ahmed

3

1 reference

30 July 2017

Paul Arundel

5

1 reference

30 July 2017

Jean-Pierre Devogelaer

7

1 reference

30 July 2017

Thomas Hangartner

8

1 reference

30 July 2017

Eva Hosszú

9

1 reference

30 July 2017

Joseph M Lane

10

1 reference

30 July 2017

Ana Paredes

14

1 reference

30 July 2017

Helene Pavlov

15

1 reference

30 July 2017

Horacio Plotkin

16

1 reference

30 July 2017

Cathleen L Raggio

17

1 reference

30 July 2017

Maria Loreto Reyes

18

1 reference

30 July 2017

Eckhard Schoenau

19

1 reference

30 July 2017

David O Sillence

21

1 reference

30 July 2017

language of work or name

English

0 references

publication date

6 August 2013

1 reference

30 July 2017

1 reference

30 July 2017

382

1 reference

30 July 2017

9902

1 reference

30 July 2017

1424-1432

1 reference

Genetic heterogeneity in osteogenesis imperfecta

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Osteogenesis imperfecta: a genetic, radiological, and epidemiological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Hearing loss in children with osteogenesis imperfecta.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Characterising and treating osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Bisphosphonates for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Intravenous pamidronate treatment in osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Two doses of pamidronate in infants with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Bisphosphonate therapy for osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Impact of alendronate on quality of life in children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Vertebral fracture assessment using a semiquantitative technique.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961091-0

7 January 2021

10.1016/S0140-6736(13)61091-0

Identifiers

DOI

1 reference

30 July 2017

1 reference